Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes
Status:
Completed
Trial end date:
2018-10-09
Target enrollment:
Participant gender:
Summary
Atrial fibrillation is when the heart's two upper chambers (called atria) beat chaotically
and irregularly, out of coordination with the two lower chambers (called ventricles) of the
heart. This can lead to blood clots forming in the heart chamber.
Patients with atrial fibrillation will be treated with either 60 mg or 75 mg of edoxaban for
up to 12 months, with a 2-4 week follow-up, after which their participation is complete.
Blood samples will be collected before the first dose of study drug (Day 0), and on Days 30,
90 and 360 (at pre dose, 1-2 hours post dose and 4-8 hours post-dose).